-
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Not Recruiting
More
This phase III clinical trial is studying how well cisplatin-based chemotherapy and/or
surgery works in treating young patients with stage I, stage II, stage III or stage IV
adrenocortical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal
tissue that needs to be removed. Giving it after surgery may kill any tumor cells that remain
after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pediatric Hematology/Oncology, 6504978953.
Stanford Investigators
View full details
-
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Colony-stimulating factors, such as G-CSF, may increase the number of immune cells found in
bone marrow or peripheral blood and may help the immune system recover from the side effects
of chemotherapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Topotecan may
make tumor cells more sensitive to radiation therapy . Giving topotecan and G-CSF together
with radiation therapy may be an effective treatment for brain stem glioma.
PURPOSE: This phase I/II trial is studying the side effects and best dose of topotecan when
given together with G-CSF and radiation therapy and to see how well they work in treating
young patients with newly diagnosed brain stem glioma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Not Recruiting
More
This phase II trial is studying the side effects and how well cixutumumab works in treating
patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as
cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells
to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
substances to them.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
Not Recruiting
More
This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase
inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or
refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor
RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink
the tumor so that it is no longer present by conventional imaging and tumor markers from
serum and cerebrospinal fluid. Radiation therapy uses high-energy x-rays to damage tumor
cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of
chemotherapy drugs and kill more tumor cells. Combining different types of therapy may kill
more tumor cells.
PURPOSE: This Phase II trial is studying how well neoadjuvant chemotherapy with or without
surgery and with or without high dose chemotherapy and peripheral stem cell transplantation,
can increase response rates prior to radiation therapy and increase progression free and
overall surviving patients with newly diagnosed intracranial germ cell tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
Not Recruiting
More
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIGB), may carry
radiation directly to tumor cells and not harm normal cells. Drugs used in chemotherapy, such
as irinotecan and vincristine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving iodine I 131 MIGB
together with irinotecan and vincristine may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of iodine I 131 MIGB
when given together with irinotecan and vincristine in treating young patients with resistant
or relapsed high-risk neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This clinical trial is studying risk-group classification of patients with newly diagnosed
acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors
assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical
trials.
Stanford is currently not accepting patients for this trial.
For more information, please contact LPCH New Patient Coordinator, 6507251072.
Stanford Investigators
View full details
-
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
Not Recruiting
More
This phase I trial is studying the side effects and best dose of lenalidomide in treating
young patients with relapsed or refractory solid tumors or myelodysplastic syndromes.
Lenalidomide may stop the growth of solid tumors or myelodysplastic syndromes by blocking
blood flow to the cancer. It may also stimulate the immune system in different ways and stop
cancer cells from growing.
Stanford is currently not accepting patients for this trial.
For more information, please contact LPCH New Patient Coordinator, 6507251072.
Stanford Investigators
View full details
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Not Recruiting
More
This randomized phase III trial is studying two different combination chemotherapy regimens
to compare how well they work when given together with radiation therapy in treating patients
with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine
sulfate, dactinomycin, cyclophosphamide, and irinotecan hydrochloride, work in different ways
to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination
chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known
which combination chemotherapy regimen is more effective when given together with radiation
therapy in treating patients with rhabdomyosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
Not Recruiting
More
This randomized phase III trial studies how well combination chemotherapy (vincristine
sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan
hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in
treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as
muscle), and has an intermediate chance of coming back after treatment (intermediate risk).
Drugs used work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Combination
chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. It is not yet known whether chemotherapy plus temsirolimus is
more effective than chemotherapy alone in treating patients with intermediate-risk
rhabdomyosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.
Not Recruiting
More
To evaluate the safety, efficacy and pharmacokinetics of nilotinib over time in the Ph+
chronic myelogenous leukemia (CML) in pediatric patients (from 1 to <18 years).
Stanford is currently not accepting patients for this trial.
For more information, please contact Contact, 650-723-5117.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Not Recruiting
More
This randomized phase III trial is studying different combination chemotherapy regimens and
their side effects and comparing how well they work in treating young patients with newly
diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
may kill more cancer cells. It is not yet known which combination chemotherapy regimen is
more effective in treating T-cell acute lymphoblastic leukemia or T-cell lymphoblastic
lymphoma. After a common induction therapy, patients were risk assigned and eligible for one
or both post-induction randomizations: Escalating dose Methotrexate versus High Dose
Methotrexate in Interim Maintenance therapy, No Nelarabine versus Nelarabine in Consolidation
therapy. T-ALL patients are risk assigned as Low Risk, Intermediate Risk or High Risk. Low
Risk patients are not eligible for the Nelarabine randomization, Patients with CNS disease at
diagnosis were assgined to receive High Dose Methotrexate, patients who failed induction
therapy were assigned to receive Nelarabine and High Dose Methotrexate. T-LLy patients were
all assigned to escalating dose Methotrexate and were risk assigned as Standard Risk, High
Risk and induction failures. Standard risk patients did not receive nelarabine, High risk
T-LLy patients were randomized to No Nelarabine versus Nelarabine, and Induction failures
were assigned to receive Nelarabine.
Stanford is currently not accepting patients for this trial.
For more information, please contact Pediatric Hematology/Oncology, 6504978953.
Stanford Investigators
View full details
-
Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
Not Recruiting
More
This natural history study is collecting health information about infants with adrenal masses
found on prenatal and/or neonatal imaging. Gathering information over time from imaging and
laboratory tests of infants with adrenal masses may help doctors learn more about the disease
and plan the best treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa Marina, 6507235535.
Stanford Investigators
View full details
-
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
Not Recruiting
More
This phase III trial is studying how well radiation therapy, amifostine, and chemotherapy
work in treating young patients with newly diagnosed nasopharyngeal cancer. Radiation therapy
uses high-energy x-rays to kill tumor cells. Drugs, such as amifostine, may protect normal
cells from the side effects of radiation therapy. Drugs used in chemotherapy, such as
cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving radiation therapy together
with amifostine and chemotherapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jenniver Lew, 6507254318.
Stanford Investigators
View full details
-
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Not Recruiting
More
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or
surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving
combination chemotherapy together with radiation therapy before surgery may make the tumor
smaller and reduce the amount of normal tissue that needs to be removed.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
Not Recruiting
More
This phase II trial is studying how well giving sulindac together with tamoxifen works in
treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may
fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more
cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Not Recruiting
More
This randomized phase III trial is studying combination chemotherapy followed by surgery and
two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to
compare how well they work in treating patients with osteosarcoma. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Biological therapies, such as PEG-interferon alfa-2b, may interfere with
the growth of tumor cells. Giving combination chemotherapy before surgery may shrink the
tumor so it can be removed. Giving combination chemotherapy together with PEG-interferon
alfa-2b after surgery may kill any remaining tumor cells. It is not yet known whether giving
combination therapy together with PEG-interferon alfa-2b is more effective than two different
combination chemotherapy regimens alone after surgery in treating osteosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Ixabepilone in Treating Young Patients With Refractory Solid Tumors
Not Recruiting
More
This phase II trial is studying how well ixabepilone works in treating young patients with
refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Norman Lacayo, 6507235535.
Stanford Investigators
View full details
-
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Not Recruiting
More
This phase I trial is studying the side effects and best dose of vorinostat when given
together with isotretinoin in treating young patients with recurrent or refractory solid
tumors, lymphoma, or leukemia. Drugs used in chemotherapy, such as vorinostat, work in
different ways to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. Vorinostat may also stop the growth of cancer cells by blocking some of
the enzymes needed for cell growth and by blocking blood flow to the cancer. Isotretinoin may
cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving
vorinostat together with isotretinoin may be an effective treatment for cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide, prednisone, and
methylprednisolone use different ways to stop cancer cells from dividing so they stop growing
or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them
or deliver cancer-killing substances to them without harming normal cells. Combining
cyclophosphamide and either prednisone or methylprednisolone with rituximab may be effective
in treating lymphoproliferative disease following organ transplantation.
PURPOSE: Phase II trial to study the effectiveness of combining cyclophosphamide and either
prednisone or methylprednisolone with rituximab in treating patients who have Epstein-Barr
virus-positive lymphoproliferative disease following organ transplantation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. It is not yet known which regimen of combination chemotherapy is
most effective for lymphoblastic lymphoma.
PURPOSE: This randomized phase III trial is studying different regimens of combination
chemotherapy to compare how well they work in treating children or adolescents with newly
diagnosed stage III or stage IV lymphoblastic lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Not Recruiting
More
This study is collecting and storing malignant, borderline malignant neoplasms, and related
biological samples from young patients with cancer. Collecting and storing samples of tumor
tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help
the study of cancer in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Enrollment on the Childhood Cancer Research Network (CCRN) of the Children s Oncology Group
Not Recruiting
More
Background:
- The Children s Oncology Group has established a research network, the Childhood Cancer
Research Network (CCRN), to collect information about children with cancer and other
conditions that are benign but involve abnormal cell growth in order to help doctors and
scientists better understand childhood cancer. The CCRN's goal is to collect clinical
information about every child diagnosed with cancer and similar conditions in the United
States and Canada, to allow researchers to study patterns, characteristics, and causes of
childhood cancer. The information can also help researchers study the causes of childhood
cancer. To expand the CCRN, parents of children who have been diagnosed with cancer will be
asked to provide information about themselves and their child for research purposes.
Objectives:
- To obtain informed consent from parents (and the child, when appropriate) of infants,
children, adolescents, and young adults newly diagnosed with cancer to enter their names
and certain information concerning their child into the Childhood Cancer Research
Network.
- To obtain informed consent from parents (and the child, when appropriate) of infants,
children, adolescents, and young adults newly diagnosed with cancer for permission to be
contacted in the future to consider participating in non-therapeutic and prevention
research studies involving the parents and/or the child.
Eligibility:
- Parents of children who have been seen at or treated by a hospital that is a member of the
Children s Oncology Group.
Design:
- Parents will provide permission to have personal information sent from their child s
hospital to the CCRN, including the child and parents' names; child's gender, birth
date, race, and ethnicity; information about the disease; and the treating institution.
- Parents will also give permission for CCRN to contact the diagnostic laboratory to
obtain specific information about the tumor or cancer cells.
- Parents will be asked if they are willing to be contacted in the future to consider
participating in CCRN research studies, and will provide contact information (name, home
address, and telephone number) to be entered in the CCRN.
- Parents or patients who change their minds about having information available in the
CCRN can ask the treatment institution to restrict access to the identifying
information. Parents or patients who refuse to have information included in the CCRN or
be contacted in the future will still be able to enter clinical cancer research studies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as carboplatin, cyclophosphamide, etoposide, and
doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Isotretinoin may help neuroblastoma
cells become more like normal cells, and grow and spread more slowly. Giving combination
chemotherapy before surgery may make the tumor smaller and make it more likely that the tumor
can be surgically removed. It is not yet known what is the minimal amount of chemotherapy
needed to achieve sufficient tumor shrinkage to control intermediate risk neuroblastoma and
prevent tumor recurrence or metastases.
PURPOSE: This phase III trial is designed to reduce therapy for patients with favorable
biology intermediate risk neuroblastoma by decreasing the number of chemotherapy cycles
administered and by allowing for up to 50% residual tumor volume for patients with localized
disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Enas Mohamed, 6507251662.
Stanford Investigators
View full details
-
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia
Not Recruiting
More
This phase II trial is studying the side effects of and how well alisertib works in treating
young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 650497881.
Stanford Investigators
View full details
-
A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.
Not Recruiting
More
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the
treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute
lymphoblastic leukemia (ALL) who have had at least 2 prior treatment regimens. This use is
based on the induction of complete responses. Randomized trials demonstrating increased
survival or other clinical benefit have not been conducted.
The purpose of the phase 1 portion of this study was to determine if clofarabine added to a
combination of etoposide and cyclophosphamide is safe in children with relapsed or refractory
acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). The purpose of the
phase 2 portion of the study was to measure the effectiveness of the combination therapy in
children with ALL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Childhood Cancer Survivor Study
Recruiting
More
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer
and its associated therapies. A retrospective cohort study will be conducted through a
multi-institutional collaboration, which will involve the identification and active follow-up
of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age,
between 1970 and 1999 and 10,000 sibling controls. This project will study children and young
adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or
surgery, who are at increased risk of late-occurring adverse health outcomes. A group of
sibling controls will be identified and data collected for comparison purposes.
Stanford Investigators
View full details
-
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
Not Recruiting
More
This research study is collecting and storing samples of bone marrow and blood from patients
with relapsed acute lymphoblastic leukemia or relapsed non-Hodgkin lymphoma. Collecting and
storing samples of bone marrow and blood from patients with cancer to study in the laboratory
may help doctors learn more about cancer and help predict the recurrence of cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Favorable-Risk Hodgkin Lymphoma
Not Recruiting
More
This phase II trial is studying how well combination chemotherapy with or without radiation
therapy works in treating young patients with favorable-risk Hodgkin lymphoma. Drugs used in
chemotherapy, such as doxorubicin hydrochloride, vinblastine, mechlorethamine hydrochloride,
vincristine sulfate, bleomycin, etoposide, and prednisone, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
more than one drug (combination chemotherapy) may kill more cancer cells. Radiation therapy
uses high-energy x-rays to kill cancer cells for those patients that still had residual
cancer at the end of chemotherapy. Giving combination chemotherapy with radiation therapy may
kill more cancer cells and allow doctors to save the part of the body where the cancer
started.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Not Recruiting
More
This phase II trial is studying how well trabectedin works in treating young patients with
recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in
chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they
stop growing or die.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
Not Recruiting
More
This research study is collecting and storing samples of tumor tissue, bone marrow, and blood
from patients with Ewing sarcoma. Collecting and storing samples of tumor tissue, bone
marrow, and blood from patients with cancer to test in the laboratory may help the study of
cancer in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
Not Recruiting
More
This phase III trial is studying how well combination chemotherapy works in treating young
patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes. Drugs
used in chemotherapy work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing. Giving more than one drug (combination
chemotherapy) may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Dechant, 6507243063.
Stanford Investigators
View full details
-
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
Not Recruiting
More
This clinical trial is studying the side effects of combination chemotherapy and to see how
well they work in treating patients with newly diagnosed localized Ewing sarcoma family of
tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug
(combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Recruiting
More
The primary aim of this randomized phase III trial was to study whether the addition of
maintenance chemotherapy delivered after surgical resection and focal radiation would be
better than surgery and focal radiation alone. The trial also studied if patients who
received induction chemotherapy and then either achieved a complete response or went on to
have a complete resection would also benefit from maintenance chemotherapy. Children ages
1-21 years with newly diagnosed intracranial ependymoma were included. There were 2 arms that
were not randomized. One arm studied patients with Grade II tumors located in the
supratentorial compartment that were completely resected. One arm studied patients with
residual tumor and those patients all received maintenance chemotherapy after focal
radiation. Chemotherapy drugs, such as vincristine sulfate, carboplatin, cyclophosphamide,
etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy
uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a
high dose of radiation directly to the tumor may kill more tumor cells and cause less damage
to normal tissue. Giving chemotherapy in combination with radiation therapy may kill more
tumor cells and allow doctors to save the part of the body where the cancer started.
Stanford Investigators
View full details
-
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Not Recruiting
More
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin,
and sargramostim to see how well it works compared to isotretinoin alone following stem cell
transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as
isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal
antibodies, such as dinutuximab, may block tumor growth in different ways by targeting
certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to
kill cancer cells. It is not yet known if chemotherapy is more effective with or without
dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating
neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Study of Blood Samples From Newborns With Down Syndrome
Not Recruiting
More
This research study is looking at blood samples from newborns with Down syndrome. Studying
the genes expressed in samples of blood from patients with Down syndrome may help doctors
identify biomarkers related to cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as valproic acid, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Valproic acid may also stop the growth of solid tumors or CNS tumors by blocking blood flow
to the tumor.
PURPOSE: This phase I trial is studying the side effects and best dose of valproic acid in
treating patients with recurrent or refractory solid tumors or CNS tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact LPCH New Patient Coordinator, 6507251072.
Stanford Investigators
View full details
-
Neuroblastoma Biology Study
Recruiting
More
Medical scientists want to find better ways to treat neuroblastoma and to find ways to
prevent the tumor from growing back. To do this, they need more information about the
characteristics of neuroblastoma cells. Therefore, they want to study samples of
neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that
may be related to the growth of neuroblastoma cells. Doctors and other medical scientists
also want to find better ways to detect and measure neuroblastoma to improve the ability to
follow the response of tumor cells to therapy.
Stanford Investigators
View full details
-
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
Not Recruiting
More
This randomized phase III trial is studying cyclophosphamide, prednisone, and immunoglobulin
to see how well they work compared to cyclophosphamide and prednisone alone in treating
patients with abnormal trunk muscle movements associated with neuroblastoma. Drugs used in
chemotherapy, work in different ways to stop tumor cells from dividing so they stop growing
or die. Steroid therapy decreases inflammation. Combining chemotherapy and steroid therapy
with immunoglobulin may be effective in treating abnormal muscle movement associated with
neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa Marina, 6507235535.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This phase III trial studies combination chemotherapy with or without lestaurtinib with to
see how well they work in treating younger patients with newly diagnosed acute lymphoblastic
leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. It is not yet known whether combination chemotherapy is more
effective with or without lestaurtinib in treating acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
Not Recruiting
More
This randomized phase III trial is studying different chemotherapy regimens given with or
without radiation therapy to compare how well they work in treating children with newly
diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer
cells from dividing so they stop growing or die. Giving the drugs in different combinations
may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells.
It is not yet known if chemotherapy is more effective with or without additional chemotherapy
and/or radiation therapy in treating Hodgkin's disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial is studying dexamethasone to see how well it works compared
to prednisone during induction therapy. This trial is also studying methotrexate and
leucovorin calcium to see how well they work compared to methotrexate alone during
maintenance therapy in treating patients with newly diagnosed acute lymphoblastic leukemia
(ALL). Drugs used in chemotherapy, such as dexamethasone, prednisone, methotrexate, and
leucovorin calcium, work in different ways to stop cancer cells from dividing so they stop
growing or die. Giving more than one drug may kill more cancer cells. It is not yet known
which combination chemotherapy regimen is more effective in treating acute lymphoblastic
leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Not Recruiting
More
This clinical trial is looking at brain function in young patients receiving methotrexate for
acute lymphoblastic leukemia. Learning about the long-term effects of methotrexate on brain
function may help doctors plan cancer treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Not Recruiting
More
This randomized phase II trial studies how well giving temozolomide and irinotecan
hydrochloride together with or without bevacizumab works in treating young patients with
recurrent or refractory medulloblastoma or central nervous system (CNS) primitive
neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan
hydrochloride, work in different ways to stop the growth of tumor cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal
antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the
ability of tumor cells to grow and spread. Others find tumor cells and help kill them or
carry tumor-killing substances to them. It is not yet known whether temozolomide and
irinotecan hydrochloride are more effective with or without bevacizumab in treating
medulloblastoma or CNS primitive neuroectodermal tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Recruiting
More
This research trial studies biomarkers in tumor tissue samples from patients with newly
diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from
patients with cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer.
Stanford Investigators
View full details
-
Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia
Not Recruiting
More
This clinical trial is studying the side effects of Erwinia asparaginase and what happens to
the drug in the body in treating young patients with acute lymphoblastic leukemia who are
allergic to PEG-asparaginase. Drugs used in chemotherapy, such as Erwinia asparaginase, work
in different ways to stop the growth of cancer cells, either by killing the cells or by
stopping them from dividing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
Not Recruiting
More
The purpose of this study is to determine how long patients who undergo complete surgical
removal of recurrent osteosarcoma in the lung will remain free of cancer after taking
Saracatinib compared to patients taking placebo (a sugar pill).
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
Not Recruiting
More
Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic
testing may help predict how cancer will respond to treatment and allow doctors to plan more
effective therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Not Recruiting
More
RATIONALE: In this study a combination of anti-cancer drugs (chemotherapy) is used to treat
brain tumors in young children. Using chemotherapy gives the brain more time to develop
before radiation is given. The chemotherapy in this study includes the drug methotrexate.
This drug was an important part of the two clinical trials which resulted in the best
survival results for children less than 3 years of age with medulloblastoma. Most patients
treated on this trial will also receive radiation which is carefully targeted to the area of
the tumor. This type of radiation (focal conformal or proton beam radiotherapy) may result in
fewer problems with thinking and learning than radiation to the whole brain and spinal cord.
PURPOSE: This clinical trial is studying how well giving combination chemotherapy together
with radiation therapy works in treating young patients with newly diagnosed central nervous
system tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This phase II/III trial is studying the side effects and how well giving dasatinib together
with combination chemotherapy works in treating young patients with newly diagnosed acute
lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle DeChant, 6507243063.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Not Recruiting
More
This randomized phase III trial studies how well combination chemotherapy works in treating
young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come
back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase
inhibitor (TKI) sensitive mutations. Chemotherapy drugs, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving
the drugs in different doses and in different combinations may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
Not Recruiting
More
This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18
together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell
transplant in treating patients with neuroblastoma. Monoclonal antibodies, such as Ch14.18,
may find tumor cells and help kill them. Colony-stimulating factors, such as sargramostim,
may increase the number of immune cells found in bone marrow or peripheral blood. Aldesleukin
may stimulate the white blood cells to kill tumor cells. Isotretinoin may help neuroblastoma
cells become more like normal cells, and to grow and spread more slowly. Giving monoclonal
antibody Ch14.18 with sargramostim, aldesleukin, and isotretinoin after autologous stem cell
transplant may be an effective treatment for neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Erwinase Master Treatment Protocol
Not Recruiting
More
The purpose of this study is to make Erwinase available to patients with acute lymphoblastic
leukemia (ALL) who have had previous allergic reactions to certain formulations of
L-asparaginase.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Not Recruiting
More
This phase I trial is studying the side effects and the best dose of vorinostat when given
together with isotretinoin to see how well it works in treating patients with high-risk
refractory or recurrent neuroblastoma. Vorinostat may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth. Isotretinoin may help vorinostat work
better by making tumor cells more sensitive to the drug. Giving vorinostat together with
isotretinoin may be an effective treatment for neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mario DeSouza, 6507243063.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Not Recruiting
More
This phase III trial is studying combination chemotherapy to see how well it works in
treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
Not Recruiting
More
This randomized pilot clinical trial is studying the side effects and how well giving
temozolomide and cixutumumab together with combination chemotherapy works in treating
patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Giving
temozolomide and cixutumumab together with combination chemotherapy may kill more tumor
cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Muktar Nadeem, 6504978815.
Stanford Investigators
View full details
-
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Recruiting
More
This phase II trial studies how well dinutuximab works when given with sargramostim in
treating patients with osteosarcoma that has come back after treatment (recurrent).
Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them.
Sargramostim may help the body increase the amount of white blood cells it produces, which
help the body fight off infections. Giving dinutuximab with sargramostim may work better and
kill more cancer cells.
Stanford Investigators
View full details
-
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Not Recruiting
More
This phase III trial is studying the side effects and how well giving combination
chemotherapy together with autologous stem cell transplant and/or radiation therapy works in
treating young patients with extraocular retinoblastoma. Giving chemotherapy before an
autologous stem cell transplant stops the growth of tumor cells by stopping them from
dividing or killing them. After treatment, stem cells are collected from the patient's blood
and/or bone marrow and stored. More chemotherapy is given to prepare the bone marrow for the
stem cell transplant. The stem cells are then returned to the patient to replace the
blood-forming cells that were destroyed by the chemotherapy. Radiation therapy uses high
energy x-rays to kill tumor cells. Giving radiation therapy after combination chemotherapy
and/or autologous stem cell transplant may kill any remaining tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lan Wang, 6507235535.
Stanford Investigators
View full details
-
Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Not Recruiting
More
This Phase II trial is studying how well giving epratuzumab together with an established
chemotherapy platform works in treating young patients with relapsed acute lymphoblastic
leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in
different ways to stop the growth of cancer cells, either by killing them or by stopping them
from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer
cells more effectively.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma
Not Recruiting
More
The purpose of this study is to collect and store samples of blood and tumor tissue from
patients with osteosarcoma. Collecting and storing samples of tumor tissue and blood from
patients to test in the laboratory may help the study of cancer in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
Not Recruiting
More
This randomized phase III trial studies different chemotherapy and radiation therapy regimens
to compare how well they work in treating young patients with newly diagnosed, previously
untreated, high-risk medulloblastoma. Drugs used in chemotherapy, such as vincristine
sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Carboplatin
may make tumor cells more sensitive to radiation therapy. It is not yet known which
chemotherapy and radiation therapy regimen is more effective in treating brain tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
Peripheral stem cell transplantation may allow the doctor to give higher doses of
chemotherapy and kill more tumor cells. It is not yet known if combination chemotherapy is
more effective with or without radiation therapy and/or surgery in treating Ewing's sarcoma.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy
regimens to see how well they work when given with or without peripheral stem cell
transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
Not Recruiting
More
This randomized phase III trial compares two different high-dose chemotherapy regimens
followed by a stem cell transplant in treating younger patients with high-risk neuroblastoma.
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving combination chemotherapy
before surgery may make the tumor smaller and reduce the amount of normal tissue that needs
to be removed. Giving these treatments before a peripheral blood stem cell transplant helps
kill any tumor cells that are in the body and helps make room in the patient?s bone marrow
for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected
from the patient's blood and stored. High-dose chemotherapy and radiation therapy is then
given to prepare the bone marrow for the stem cell transplant. The stem cells are then
returned to the patient to replace the blood-forming cells that were destroyed by the high-
chemotherapy. It is not yet known which regimen of high-dose chemotherapy is more effective
for patients with high-risk neuroblastoma undergoing a peripheral blood stem cell transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem mukhtar, 6507251662.
Stanford Investigators
View full details
-
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Not Recruiting
More
This phase II trial is studying how well etanercept works in treating young patients with
idiopathic pneumonia syndrome after undergoing a donor stem cell transplant. Etanercept may
be effective in treating patients with idiopathic pneumonia syndrome after undergoing a donor
stem cell transplant.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
Not Recruiting
More
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during
surgery.
PURPOSE: Phase II trial to determine the effectiveness of specialized radiation therapy
either alone or after chemotherapy and second surgery in treating children who have undergone
surgery for localized ependymoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized clinical trial is studying giving calaspargase pegol together with
combination chemotherapy to see how well it works compared with giving pegaspargase together
with combination chemotherapy in treating younger patients with newly diagnosed high-risk
acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving
more than one drug (combination chemotherapy) may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
A Study of R1507 in Participants With Recurrent or Refractory Sarcoma
Not Recruiting
More
The study was primarily designed to determine objective response, progression-free survival
(PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory
Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas
including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal
myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6507256413.
Stanford Investigators
View full details
-
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from
dividing so they stop growing or die. Giving combination chemotherapy before surgery may
shrink the tumor so that it can be removed. Giving combination chemotherapy after surgery may
kill any remaining tumor cells.
PURPOSE: This phase II trial is studying how well surgery and/or combination chemotherapy
work in treating children with fibrosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Not Recruiting
More
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients
with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block
tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them.
Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Giving cixutumumab and temsirolimus together may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Amie Denisova, 6504978966.
Stanford Investigators
View full details
-
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as temozolomide, vincristine, and irinotecan,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when
given together with temozolomide and vincristine in treating young patients with refractory
solid tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Assessing the long-term effects of cancer treatment in cancer survivors may help
improve the ability to plan effective treatment and follow-up care.
PURPOSE: This clinical trial is studying the long-term effects of treatment in patients who
were previously treated for childhood Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Not Recruiting
More
Participants that were assigned to the oral etoposide treatment arm in protocol OSI-774-205
and either progressed while on study or discontinued due to unacceptable toxicity related to
etoposide were allowed to participate in this study to assess the safety profile of
single-agent erlotinib in participants with recurrent or refractory pediatric ependymoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
A Study of Pemetrexed in Children With Recurrent Cancer
Not Recruiting
More
To determine the response rate of pemetrexed given every 21 days for the treatment of
children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive
neuroectodermal tumors (PNET), rhabdomyosarcoma, neuroblastoma, ependymoma,
medulloblastoma/supratentorial PNET or non-brain stem high-grade glioma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Not Recruiting
More
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with
ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors
to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help
in diagnosing patients correctly and may result in more timely treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Muehe, (650) 724-3191.
Stanford Investigators
View full details
-
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
Not Recruiting
More
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly
diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia
involves high doses of a common class of chemotherapy drugs called anthracyclines, which are
known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth
of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may
stop the growth of cancer cells by either killing the cells, by stopping them from dividing,
or by stopping them from spreading. Completely removing or reducing the amount of
anthracycline chemotherapy and giving tretinoin together with arsenic trioxide may be an
effective treatment for acute promyelocytic leukemia and may reduce some of the long-term
side effects.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Consent for Obtaining Additional Bone Marrow Specimens at Time of Diagnostic Bone Marrow Procedure
Not Recruiting
More
The purpose of this study is to collect bone marrow samples for experimental studies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Christina Baggott, .
Lead Sponsor
Stanford Investigators
View full details
-
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Not Recruiting
More
This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide
with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that
has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan
hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and
help kill them or carry tumor-killing substances to them. It is not yet known whether giving
irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more
effective in treating neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Not Recruiting
More
To determine the activity of lenalidomide in the treatment of pediatric subjects with
relapsed/refractory acute myeloid leukemia (AML) (with second or greater relapse or
refractory to at least 2 prior induction attempts) measured by morphological complete
response defined as either a CR or CRi within the first 4 cycles of treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This research trial studies a risk-based classification system for patients with newly
diagnosed acute lymphoblastic leukemia. Gathering health information about patients with
acute lymphoblastic leukemia may help doctors learn more about the disease and plan the best
treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Not Recruiting
More
This randomized phase III trial compares how well combination chemotherapy works when given
with or without bortezomib in treating patients with newly diagnosed T-cell acute
lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. Bortezomib may help
reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for
cell growth. It may also help chemotherapy work better by making cancer cells more sensitive
to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib
is more effective in treating newly diagnosed T-cell acute lymphoblastic leukemia and T-cell
lymphoblastic lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
Not Recruiting
More
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving
cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than
no additional treatment in preventing hearing loss.
PURPOSE: This randomized phase III trial is studying sodium thiosulfate to see how well it
works in preventing hearing loss in young patients receiving cisplatin for newly diagnosed
germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, osteosarcoma, or other
malignancy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
Not Recruiting
More
This randomized phase III trial studies how well combination chemotherapy with or without
ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to
other parts of the body. Treatment with drugs that block the IGF-1R pathway, such as
ganitumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in
chemotherapy, such as vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide,
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. It is not yet known whether
adding ganitumab to combination chemotherapy is more effective in treating patients with
newly diagnosed metastatic Ewing sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Not Recruiting
More
This phase II trial is studying how well giving radiation therapy together with temozolomide
and lomustine works in treating young patients with newly diagnosed gliomas. Radiation
therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as
temozolomide and lomustine, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Giving radiation therapy together
with temozolomide and lomustine after surgery may kill any remaining tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors
Not Recruiting
More
This phase II trial is studying how well giving combination chemotherapy works in treating
young patients with recurrent or resistant malignant germ cell tumors. Drugs used in
chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Pharmacokinetics of Daunorubicin in Young Patients With Cancer
Not Recruiting
More
This laboratory study is looking at the pharmacokinetics of daunorubicin in young patients
with cancer. Collecting and storing samples of blood from patients with cancer to study in
the laboratory may help doctors learn more about how patients respond to treatment with
certain chemotherapy drugs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson A. Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
Not Recruiting
More
RATIONALE: Modafinil may help improve memory, attention, and fatigue caused by cancer
treatment.
PURPOSE: This phase II randomized trial studies how well modafinil works in treating children
with memory and attention problems caused by cancer treatment for a brain tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from
dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage
cancer cells. Giving combination chemotherapy together with radiation therapy may kill more
cancer cells.
PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation
therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the
CNS and/or testes.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor
Not Recruiting
More
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in
chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or
die. It is not yet known whether radiation therapy alone is as effective as chemotherapy plus
radiation therapy in treating germ cell tumor.
PURPOSE: This randomized phase III trial is studying radiation therapy alone to see how well
it works compared to chemotherapy and radiation therapy in treating patients with newly
diagnosed primary CNS germ cell tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy
Not Recruiting
More
This study is designed to collect tissue samples that may aid in the treatment and learning
about various oncology diagnosis.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, .
Lead Sponsor
Stanford Investigators
View full details
-
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Not Recruiting
More
This partially randomized phase III trial studies the side effects of different combinations
of risk-adapted chemotherapy regimens and how well they work in treating younger patients
with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic
lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving more than
one drug (combination chemotherapy), giving the drugs in different doses, and giving the
drugs in different combinations may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Not Recruiting
More
This phase III trial studies how well response and biology-based risk factor-guided therapy
works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may
not need treatment until it progresses. In this case, observation may be sufficient.
Measuring biomarkers in tumor cells may help plan when effective treatment is necessary and
what the best treatment is. Response and biology-based risk factor-guided therapy may be
effective in treating patients with non-high risk neuroblastoma and may help to avoid some of
the risks and side effects related to standard treatment.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-498-7061.
Stanford Investigators
View full details
-
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Not Recruiting
More
This randomized phase II/III trial studies how well pazopanib, when combined with
chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of
patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually
be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs
used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some
of the enzymes needed for cell growth. It is not yet known whether these therapies can be
safely combined and if they work better when given together in treating patients with
non-rhabdomyosarcoma soft tissue sarcomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa M. Marina, 650-498-7061.
Stanford Investigators
View full details
-
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial studies how well blinatumomab works compared with standard
combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that
has returned after a period of improvement (relapsed). Immunotherapy with blinatumomab may
allow the body's immune system to attack and destroy some types of leukemia cells. It is not
yet known whether blinatumomab is more effective than standard combination chemotherapy in
treating relapsed B-cell acute lymphoblastic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Recruiting
More
This phase I/II trial studies the side effects and best dose of nivolumab when given with or
without ipilimumab to see how well they work in treating younger patients with solid tumors
or sarcomas that have come back (recurrent) or do not respond to treatment (refractory).
Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the
body's immune system attack the cancer, and may interfere with the ability of tumor cells to
grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab
in treating patients with recurrent or refractory solid tumors or sarcomas.
Stanford Investigators
View full details
-
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Not Recruiting
More
This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib
and combination chemotherapy works in treating patients with newly diagnosed stage II-IV
anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called
brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive
cancer cells in targeted way and delivers vedotin to kill them. Crizotinib and methotrexate
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading. It
is not yet known whether brentuximab vedotin and combination chemotherapy is more effective
than crizotinib and combination chemotherapy in treating anaplastic large cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Not Recruiting
More
The study design was an open-label Phase II pediatric clinical study. The purpose of Study
X2203 was to identify any efficacy signal in subjects with the disease subtypes under study,
when treated with pazopanib monotherapy. Furthermore, it was to define the toxicities of
pazopanib in children, as well as examine biological markers, e.g. cytokines and angiogenic
factors, that could help further characterize any response of pazopanib in children.
Pazopanib was administered as monotherapy in tablet and powder suspension formulations at
daily doses of 450 mg/m2/dose or 225 mg/m2/dose, respectively. The first 6 enrolled subjects
receiving oral suspension formulation were assessed for tolerability and extended PK
sampling; and, only if pazopanib was tolerated, subsequent subjects were enrolled at the same
starting dose with the suspension. Dose escalation was not permitted. For the tablet, a
dosing nomogram was used based on the subject's BSA. Dose reduction was dependent upon the
toxicity of pazopanib and disease status of the infants, toddlers, children, adolescents, and
young adults. Subjects could be as young as 1 year-old infants to screen for enrollment.
Subjects were assessed for initial response after 8 weeks of treatment prior to Cycle 3. A
cycle was defined as 28 days of pazopanib treatment with no rest period between cycles.
Treatment was administered continuously once daily. Treatment was to be discontinued if there
was evidence of disease progression, unacceptable treatment-related toxicity, pregnancy.
Histological classification was an important diagnostic inclusion in these subjects with a
wide variety of refractory solid tumors, i.e. 7 different tumor types and each being a
cohort.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, .
Stanford Investigators
View full details
-
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as vincristine, irinotecan, ifosfamide,
etoposide, doxorubicin, cyclophosphamide, and dactinomycin, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Giving high-dose combination
chemotherapy together with radiation therapy may kill more tumor cells.
PURPOSE: This phase III trial is studying how well giving high-dose combination chemotherapy
together with radiation therapy works in treating patients with newly diagnosed metastatic
rhabdomyosarcoma or ectomesenchymoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
Not Recruiting
More
This randomized phase III trial is studying how well standard-dose radiation therapy works
compared to reduced-dose radiation therapy in children 3-7 years of age AND how well standard
volume boost radiation therapy works compared to smaller volume boost radiation therapy when
given together with chemotherapy in treating young patients who have undergone surgery for
newly diagnosed standard-risk medulloblastoma. Radiation therapy uses high-energy x-rays to
damage tumor cells. Drugs used in chemotherapy, such as vincristine, cisplatin, lomustine,
and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop
growing or die. Giving radiation therapy with chemotherapy after surgery may kill any
remaining tumor cells. It is not yet known whether standard-dose radiation therapy is more
effective than reduced-dose radiation therapy when given together with chemotherapy after
surgery in treating young patients with medulloblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Not Recruiting
More
This randomized phase III trial studies how well bortezomib and sorafenib tosylate work in
treating patients with newly diagnosed acute myeloid leukemia. Bortezomib and sorafenib
tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell
growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Giving bortezomib and
sorafenib tosylate together with combination chemotherapy may be an effective treatment for
acute myeloid leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds/Hem Onc CRAs, (650) 497-8953.
Stanford Investigators
View full details
-
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Not Recruiting
More
This phase III trial is studying how well combination chemotherapy and radiation therapy work
in treating patients with newly diagnosed low-risk rhabdomyosarcoma. Drugs used in
chemotherapy, such as vincristine, dactinomycin, and cyclophosphamide, work in different ways
to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses
high-energy x-rays to damage tumor cells. Combining chemotherapy with radiation therapy may
kill more tumor cells. It is not yet known which treatment regimen is more effective in
treating low-risk rhabdomyosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Not Recruiting
More
This phase I trial studies the side effects and best dose of lenalidomide when given together
with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma
that does not respond to treatment or that has come back. Drugs used in chemotherapy, such as
lenalidomide and isotretinoin, work in different ways to stop the growth of tumor cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as dinutuximab, may interfere with the ability of
tumor cells to grow and spread. Giving more than one drug (combination chemotherapy) together
with dinutuximab therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Not Recruiting
More
This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after
chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come
back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops
the growth of tumor cells by stopping them from dividing or killing them. After treatment,
stem cells are collected from the patient's blood and stored. More chemotherapy or radiation
therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are
then returned to the patient to replace the blood-forming cells that were destroyed by the
chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma
Not Recruiting
More
This phase II trial study has a 6-patient feasibility portion studying the tolerability of
chemotherapy with vincristine sulfate together with topotecan hydrochloride,
cyclophosphamide, and bevacizumab in treating young patients with refractory or first
recurrent extracranial Ewing's sarcoma. If the therapy is considered tolerable, this
feasibility run-in will be followed by a randomized phase II portion studying giving
vincristine sulfate together with topotecan hydrochloride, and cyclophosphamide to see how
well it works compared with giving vincristine sulfate together with topotecan hydrochloride,
cyclophosphamide, and bevacizumab in treating young patients with refractory or first
recurrent extracranial Ewing's sarcoma. Drugs used in chemotherapy, such as vincristine
sulfate, topotecan hydrochloride, and cyclophosphamide, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Bevacizumab may also stop tumor growth by
blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab
may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
Not Recruiting
More
This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG)
and compare their effects on tumor response and associated side effects, to determine if one
therapy is better than the other for people diagnosed with relapsed or persistent
neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Not Recruiting
More
This phase I/II trial studies the side effects and the best dose of brentuximab vedotin when
given together with gemcitabine hydrochloride and to see how well they work in treating
younger patients with Hodgkin lymphoma that has returned or does not respond to treatment.
Monoclonal antibodies, such as brentuximab vedotin, may find cancer cells and help kill them.
Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving brentuximab vedotin together with gemcitabine hydrochloride may kill more cancer
cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-736-4281.
Stanford Investigators
View full details
-
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma
Not Recruiting
More
To establish whether treatment with Inhaled Lipid Cisplatin (ILC) is effective in
delaying/preventing pulmonary relapse in osteosarcoma patients in complete surgical remission
following one or two prior pulmonary relapses.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
Recruiting
More
A research study on the diagnosis of spread of disease for children who have been diagnosed
with solid tumors using a new whole body imaging technique and a new MR contrast agent
(ferumoxytol). Standard tests that are used to determine the extent and possible spread of a
child's disease include magnetic resonance (MR) imaging, computed tomography (CT), Positron
Emission Tomography (PET) as well as bone scanning, and metaiodobenzylguanidine (MIBG)
scanning. The purpose of this study is to determine if newer imaging tests referred to as
whole body diffusion-weighted MR and whole body PET/MR can detect the extent and spread of
the disease as accurately or even better as the standard tests (CT, MR and/or PET/CT). The
advantage of the new imaging test is that it is associated with no or significantly reduced
radiation exposure compared to standard CT and PET/CT imaging tests. The results of whole
body MR and PET/MR will be compared with that of the conventional, standard imaging studies
for tumor detecting.
Stanford Investigators
View full details
-
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Not Recruiting
More
This randomized phase II trial studies how well low-dose lenalidomide works compared with
high-dose lenalidomide in treating younger patients with juvenile pilocytic astrocytomas or
optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment
(refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide is
classified as an immunomodulatory drug as it boosts the immune system. It has other potential
anti-tumor effects, for example, it may stop the growth of tumor cells by blocking blood flow
to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective
than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or
optic nerve pathway gliomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 650-725-4708.
Stanford Investigators
View full details
-
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
Not Recruiting
More
This phase II trial is studying the side effects and best dose of bortezomib and to see how
well it works when given together with combination chemotherapy in treating younger patients
with recurrent, refractory, or secondary acute myeloid leukemia (AML). Bortezomib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used
in chemotherapy, such as idarubicin, cytarabine, and etoposide, work in different ways to
stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Giving more than one drug (combination chemotherapy) together with bortezomib may
kill more cancer cells
Stanford is currently not accepting patients for this trial.
For more information, please contact Lan Wang, 6507254708.
Stanford Investigators
View full details
-
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Not Recruiting
More
This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral
etoposide in patients with recurrent or refractory pediatric ependymoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
Not Recruiting
More
This trial examined the outcome benefit to patients of adding a new chemotherapy drug
combination to the established treatment approach for patients with extracranial Ewing
sarcoma, that had not spread from the primary site to other places in the body. The trial
randomly assigned patients at the time of study entry to receive established standard
treatment with the following 5-drugs: vincristine sulfate, doxorubicin hydrochloride,
cyclophosphamide, ifosfamide and etoposide. The outcome for patients receiving the standard
5-drug combination was compared to the outcome for patients who received the same 5-drugs
with an additional drug, topotecan hydrochloride delivered in a novel combination with
vincristine sulfate and cyclophosphamide.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors
Not Recruiting
More
This phase II trial studies how well linsitinib works in treating younger and adult patients
with gastrointestinal stromal tumors. Linsitinib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 650-725-6413.
Stanford Investigators
View full details
-
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Not Recruiting
More
This phase II trial studies how well sunitinib malate works in treating younger patients with
recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Christina Huang, 650-723-0574.
Stanford Investigators
View full details
-
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Not Recruiting
More
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Not Recruiting
More
This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without
radiation therapy or observation only to see how well they work in treating patients
undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs
used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving these
treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after
surgery, the tumor may not need additional treatment until it progresses. In this case,
observation may be sufficient.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lan Wang, 6507254708.
Stanford Investigators
View full details
-
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Not Recruiting
More
This phase II trial studies how well chemotherapy followed by radiation therapy work in
treating younger patients with newly diagnosed central nervous system germ cell tumors that
have not spread to other parts of the brain, spinal canal, or body (localized). Drugs used as
chemotherapy, such as carboplatin, etoposide, and ifosfamide, work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Radiation therapy uses high-energy x rays to kill tumor cells.
Giving chemotherapy followed by radiation therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial is studying different combination chemotherapy regimens and
comparing how well they work in treating patients with newly diagnosed acute lymphoblastic
leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact LPCH New Patient Coordinator, 6507251072.
Stanford Investigators
View full details
-
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Not Recruiting
More
This randomized phase III trial is studying low-dose vincristine to see how well it works
compared with high-dose vincristine when given together with different combination
chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute
lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth
of cancer cells, either by killing the cells or by stopping them from dividing. Giving more
than one drug (combination chemotherapy) and giving the drugs in different ways and different
doses may kill more cancer cells..
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
Not Recruiting
More
This phase III trial is studying observation to see how well a risk based treatment strategy
works in patients with soft tissue sarcoma. In the study, patients are assigned to receive
surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes,
after surgery, the tumor may not need additional treatment until it progresses. In this case,
observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells.
Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to
stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving these treatments
after surgery may kill any tumor cells that remain after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
Not Recruiting
More
This phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and
vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or did
not respond to previous therapy. Bortezomib is an inhibitor of protein degradation.
Bortezomib degrades short-lived regulatory proteins in the cell, and has been reported to
increase the tumor cells. Bortezomib may increase the effectiveness of ifosfamide and
vinorelbine (two standard drugs given to children with Hodgkin Lymphoma that has come back
after initial treatment) by making cancer cells more sensitive to effectiveness of standard
chemotherapy by preventing anti-death responses in these drugs. Giving bortezomib together
with ifosfamide and vinorelbine tartrate should kill more cancer cells than are killed with
ifosfamide and vinorelbine alone.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa Marina, 6507235535.
Stanford Investigators
View full details
-
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate
Not Recruiting
More
This phase I trial is studying the side effects and best dose of dasatinib in treating young
patients with recurrent or refractory solid tumors or Philadelphia chromosome-positive acute
lymphoblastic leukemia or chronic myelogenous leukemia that did not respond to imatinib
mesylate. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa Marina, 6507235535.
Stanford Investigators
View full details
-
Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation
Not Recruiting
More
Phase II trial to determine the efficacy of Dose Adjusted-EPOCH-Rituximab regimen in children
and adolescent with primary mediastinal large B cell lymphoma in terms of event free
survival.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, .
Stanford Investigators
View full details
-
Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma
Not Recruiting
More
This phase III trial is studying vincristine, carboplatin, and etoposide to see how well they
work compared to observation only in treating patients who have undergone surgery for newly
diagnosed retinoblastoma. Drugs used in chemotherapy, such as vincristine, carboplatin, and
etoposide, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy)
after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery,
no additional treatment is needed for the tumor until it progresses. In this case,
observation may be sufficient.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Not Recruiting
More
This randomized phase II/III trial is studying vorinostat, temozolomide, or bevacizumab to
see how well they work compared with each other when given together with radiation therapy
followed by bevacizumab and temozolomide in treating young patients with newly diagnosed
high-grade glioma. Vorinostat may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses
high-energy x-rays to kill tumor cells. It is not yet known whether giving vorinostat is more
effective then temozolomide or bevacizumab when given together with radiation therapy in
treating glioma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Genomic Analysis of Pediatric Bone Tumors
Not Recruiting
More
To determine whether gene expression analysis of primary tumor samples before and after
chemotherapy are predictive of long-term survival in pediatric patients with bone sarcomas
(Ewings sarcoma (ES) and Osteosarcoma(OS)).
Stanford is currently not accepting patients for this trial.
For more information, please contact Alejandro Sweet-Cordero, 650-725-5901.
Lead Sponsor
Stanford Investigators
View full details
-
Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effect on the body of combining cyclophosphamide with
cisplatin, etoposide, and bleomycin in treating children who have newly diagnosed malignant
germ cell tumors that are not in the brain and gonads.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Recruiting
More
This research trial studies neuropsychological (learning, remembering or thinking) and
behavioral outcomes in children and adolescents with cancer by collecting information over
time from a series of tests.
Stanford Investigators
View full details
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
Not Recruiting
More
This randomized phase II trial studies how well vinorelbine tartrate and cyclophosphamide
work in combination with bevacizumab or temsirolimus in treating patients with recurrent or
refractory rhabdomyosarcoma. Drugs used in chemotherapy, such as vinorelbine tartrate and
cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing
the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
Bevacizumab may also stop the growth of rhabdomyosarcoma by blocking blood flow to the tumor.
Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. It is not yet known whether combination chemotherapy is more effective when
given together with bevacizumab or temsirolimus in treating rhabdomyosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Not Recruiting
More
This phase III trial studies how well combination chemotherapy and surgery work in treating
young patients with Wilms tumor. Drugs used in chemotherapy work in different ways to stop
the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller
and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may
kill any tumor cells that remain after surgery.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-497-8953.
Stanford Investigators
View full details
-
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
Not Recruiting
More
This phase III trial is studying surgery followed by combination chemotherapy to see how well
it works in treating children with germ cell tumors that are not located in the head. Drugs
used in chemotherapy use different ways to stop tumor cells from dividing so they stop
growing or die. Combining more than one drug, and giving them after surgery, may kill any
remaining tumor cells following surgery. It is not yet known whether combination chemotherapy
is effective in decreasing the recurrence of childhood germ cell tumors.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase II trial is studying how well cytarabine works in treating young patients
with recurrent or refractory Ewing's sarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Not Recruiting
More
The purpose of this study is to determine whether Dasatinib when added to standard
chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome
positive acute lymphoblastic leukemia
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650736428.
Stanford Investigators
View full details
-
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Not Recruiting
More
RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the
growth of tumor cells and shrink the tumor so that it can be removed during surgery.
Sargramostim may then kill any tumor cells remaining after surgery. This may be an effective
treatment for osteosarcoma that has spread to the lung.
PURPOSE: This phase II trial is studying how well inhaled sargramostim works in treating
patients who are undergoing surgery for the first recurrence of osteosarcoma that has spread
to the lung.
Stanford is currently not accepting patients for this trial.
For more information, please contact Min Wang, 6507364281.
Stanford Investigators
View full details
-
Study of Kidney Tumors in Younger Patients
Recruiting
More
This research trial studies kidney tumors in younger patients. Collecting and storing samples
of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may
help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify
biomarkers related to cancer.
Stanford Investigators
View full details
-
ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
Not Recruiting
More
This phase II trial is studying how well ABT-751 works in treating children with
neuroblastoma that has relapsed or not responded to previous treatment. Drugs used in
chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing.
Stanford is currently not accepting patients for this trial.
For more information, please contact Neyssa Marina, 6507235535.
Stanford Investigators
View full details
-
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Not Recruiting
More
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in
different ways to stimulate the immune system and stop tumor cells from growing.
PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works
in treating young patients with recurrent or refractory neuroblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact LPCH New Patient Coordinator, 6507251072.
Stanford Investigators
View full details
-
Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors
Recruiting
More
This clinical trial studies cancer survivors to identify those who are at increased risk of
developing late-occurring complications after undergoing treatment for childhood cancer. A
patient's genes may affect the risk of developing complications, such as congestive heart
failure, avascular necrosis, stroke, and second cancer, years after undergoing cancer
treatment. Genetic studies may help doctors identify survivors of childhood cancer who are
more likely to develop late complications.
Stanford Investigators
View full details
-
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
Recruiting
More
This clinical trial keeps track of and collects follow-up information from patients who are
currently enrolled on or have participated in a Children's Oncology Group study. Developing a
way to keep track of patients who have participated in Children's Oncology Group studies may
allow doctors learn more about the long-term effects of cancer treatment and help them reduce
problems related to treatment and improve patient quality of life.
Stanford Investigators
View full details
-
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Not Recruiting
More
The goal of this clinical research study is to learn if the combination of Avastin
(bevacizumab) and Tykerb (lapatinib) can help to control ependymoma in pediatric patients.
The safety of this drug combination will also be studied.
Stanford is currently not accepting patients for this trial.
For more information, please contact Carissa Bailey, 6507254708.
Stanford Investigators
View full details
-
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Not Recruiting
More
This phase I/II trial is studying the side effects and best dose of sorafenib in treating
young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking
blood flow to the cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Not Recruiting
More
The purpose of this study is to collect and store tumor tissue, blood, and bone marrow
samples from patients with soft tissue sarcoma that will be tested in the laboratory.
Collecting and storing samples of tumor tissue, blood, and bone marrow from patients to test
in the laboratory may help the study of cancer.
Stanford is currently not accepting patients for this trial.
For more information, please contact Alyson Falwell, 650-726-4281.
Stanford Investigators
View full details
-
Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
cells, either by killing the cells or by stopping them from dividing. Giving more than one
drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This clinical trial is studying the side effects and best dose of zoledronic acid
when given together with combination chemotherapy in treating patients with newly diagnosed
metastatic osteosarcoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
-
Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas
Not Recruiting
More
This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn
about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients
with the EGFRvIII peptide vaccine after conventional radiation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Christina Huang, 650-723-0574.
Stanford Investigators
View full details
-
Symptom Assessment With Patient Surveys
Not Recruiting
More
The primary purpose of the proposed research is to explore methods of obtaining symptom
assessments from pediatric oncology patients and/or their caregivers in hopes of improving
the accuracy and thoroughness of these reports. Additionally the researchers hope to simply
staff efforts in obtaining detailed medical histories from pediatric oncology patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact Christina Baggott, 6504978815.
Lead Sponsor
Stanford Investigators
View full details
-
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer
Not Recruiting
More
This phase III trial studies the side effects and how well risk-based therapy works in
treating younger patients with newly diagnosed liver cancer. Surgery, chemotherapy drugs
(cancer fighting medicines), and when necessary, liver transplant, are the main current
treatments for hepatoblastoma. The stage of the cancer is one factor used to decide the best
treatment. Treating patients according to the risk group they are in may help get rid of the
cancer, keep it from coming back, and decrease the side effects of chemotherapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Not Recruiting
More
This phase II trial studies how well cilengitide works in treating younger patients with
recurrent or progressive high-grade glioma that has not responded to standard therapy.
Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.
Stanford is currently not accepting patients for this trial.
For more information, please contact Jennifer Lew, 6507254318.
Stanford Investigators
View full details
-
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Not Recruiting
More
This phase III trial is studying how well combination chemotherapy with or without radiation
therapy works in treating young patients with newly diagnosed stage III or stage IV Wilms'
tumor. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Radiation therapy uses
high-energy x-rays to kill tumor cells. Giving more than one drug (combination chemotherapy)
with or without radiation therapy may kill more tumor cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6507251662.
Stanford Investigators
View full details
-
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma
Not Recruiting
More
This research study is collecting and storing tissue samples from patients with rare or
cutaneous non-Hodgkin lymphoma. Collecting and storing samples of tissue from patients with
cancer to test in the laboratory may help the study of cancer in the future.
Stanford is currently not accepting patients for this trial.
For more information, please contact Peds Hem/Onc CRAs, 650-723-5535.
Stanford Investigators
View full details
-
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Not Recruiting
More
This pilot, phase II trial studies the side effects of giving bortezomib together with
combination chemotherapy and to see how well it works in treating young patients with
relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
cells or by stopping them from dividing. Giving bortezomib together with combination
chemotherapy may kill more cancer cells.
Stanford is currently not accepting patients for this trial.
For more information, please contact Nadeem Mukhtar, 6504978815.
Stanford Investigators
View full details
